Treatment options for

metastatic urothelial carcinoma:

Patient case studies

Urothelial carcinoma is one of the most common malignancies worldwide. For patients with metastatic urothelial carcinoma (mUC), systemic chemotherapy has been the standard of care for many years but the development of new therapeutics is starting to expand treatment options. Here, you are invited to participate in this three-part case study series, which looks at how to manage patients with mUC.

In the first case study, we follow a patient who is not eligible to receive cisplatin-based chemotherapy and look at other available options in this situation.
In the second case study, we look at first-line therapy for cisplatin-eligible patients and the following standard immune checkpoint inhibitor maintenance regimen.
In the final case study, we consider three patients whose disease has progressed after first- and/or second-line therapy, and look at available options and the clinical data behind them for these situations.

Each case study will take up to 15 minutes to complete. Review the evidence, test your knowledge through these case-based self-assessments and help guide your everyday clinical practice.

Case 1: First-line therapy for cisplatin-ineligible patients

Professor Aristotle Bamias presents an interactive case study on selecting the most adequate first-line treatment option for a cisplatin-ineligible patient.

Case 2: First-line therapy for cisplatin-eligible patients followed by maintenance therapy

Professor Jens Bedke presents an interactive case study on selecting the most adequate first-line treatment option for cisplatin-eligible patients and explains the standard maintenance therapy.

Case 3: Second- and subsequent lines of treatment for patients with mUC

Professor Cora Sternberg presents an interactive case study which follows patients whose disease has progressed after first- and/or second-line therapy and considers available treatment options for these situations.

Login to access these case studies

No account? Create a free account now

Email*
Password*
Enter Password Confirm Password
Healthcare Professional*
(Required) I confirm that I am a healthcare professional*
Privacy Acceptance*
(Required) I have read and accept the terms of the Privacy notice and the Terms and Conditions and consent to receive e-alerts from Springer Healthcare IME pertinent to my area of interest. I can withdraw my consent at any time by contacting IME@springer.com or via the ‘unsubscribe’ link included in any email communications*
SHE Communication Preferences
(Optional) I agree that my email address will be used by our sister site Medicine Matters Oncology, as per their Privacy Policy, for the purposes of communicating to me details of educational content pertinent to Oncology. I can withdraw my consent at any time by contacting medicinematters@springer.com or via the ‘unsubscribe’ link included in any email communications.
Name
This field is for validation purposes and should be left unchanged.

About this activity

Learning objectives

Case 1: First-line therapy for cisplatin-ineligible patients

After completing this case study, you will be able to:

Discuss available options for first-line treatment in patients who are ineligible to receive cisplatin-based chemotherapy
Understand clinical data behind new therapy options for first-line treatment in patients who are ineligible to receive cisplatin-based chemotherapy
Identify the best treatment strategy based on individual patient characteristics

Case 2: First-line therapy for cisplatin-eligible patients followed by maintenance therapy

After completing this case study, you will be able to:

Discuss the standard of care in first line for patients with mUC who are eligible for cisplatin-based chemotherapy
Understand the clinical data supporting immune checkpoint inhibitor (ICI) maintenance therapy after first-line treatment in patients with mUC

Case 3: Second- and subsequent lines of treatment for patients with mUC

After completing this case study, you will be able to:

Discuss available options for second- and subsequent lines of treatment in patients whose disease has progressed after first line
Understand clinical data behind new therapy options for second- and subsequent lines of treatment
Identify the best treatment strategy based on individual patient characteristics

Educational grant

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.